Case Study 2 — On the Medication: What Nobody Tells You Before, During, or After

A composite clinical case. ⚠️ The drug class, the trial findings, the side-effect profile and the discontinuation data are real; the person is constructed. ⚠️ This is not prescribing advice. GLP-1 receptor agonists are prescription medicines requiring individual clinical assessment.**

Setup

Rosalind Achebe is 54. BMI 37. Type 2 diabetes for six years, on metformin. Obstructive sleep apnoea, on CPAP. Knee osteoarthritis. A1c 7.8%.

⚠️ Nineteen years of weight-loss attempts, which she summarized in one sentence:

"I've done all of them. I'm very good at losing weight."

Her GP started semaglutide.

What follows is what happened, in the order it happened, ⚠️ including the parts that don't appear in the marketing or, frequently, in the consultation.

Months 1–3: the part that surprised her

Not the weight. The quiet.

"I didn't realize how much of my head was food until it stopped. It was like a radio being turned off in another room. I hadn't known it was on."

⚠️ This is the most consistent thing people report on these drugs and it is almost never what they were told to expect. "Food noise" — intrusive, recurrent thoughts about eating — reduces markedly.

§24.5 predicts this exactly. ⚠️ The drug acts on appetite regulation, and appetite regulation was the mechanism. She was not experiencing willpower; she was experiencing the absence of a signal she had been resisting for nineteen years.

What also happened:

⚠️ Months 3–6: the problem nobody had mentioned

She was eating around 900–1,100 kcal/day. Not deliberately.

⚠️ This is the part of the GLP-1 story that is genuinely under-managed. When appetite falls sharply, intake can fall much further than intended — and with it, protein.

💡 Aha moment. ⚠️ A substantial fraction of weight lost on these medications is lean tissue — which is true of most rapid weight loss and matters more here because the losses are larger.

And the mechanism creates the problem: the drug removes appetite, and protein is the macronutrient people drop first when appetite falls, because it's the one that requires deliberate effort to obtain.

⚠️ She was losing weight successfully and becoming functionally weaker at the same time — at 54, which is exactly when that matters (Chapter 25).

What we changed, and it should have been in place from day one:

• ⚠️ Protein target: 1.6 g/kg of current weight, prioritized at every meal. Eaten FIRST.
• Resistance training twice weekly, starting supervised because of the knee.
• ⚠️ Fibre and fluid deliberately — the constipation was making her eat less still.
• Micronutrient review — ⚠️ when total intake halves, everything in it halves (Chapters 13, 14).
• A protein-first meal structure, because with a small appetite the order of eating determines what gets eaten at all.

Months 6–14

⚠️ The metabolic outcomes here are not the same category of thing as the weight. A1c 7.8 → 6.1 with reduced medication burden and improved sleep apnoea is a clinically meaningful set of changes, and Chapter 26 explains why weight loss of this magnitude produces them.

⚠️ The conversation nobody had had

At month 14 she asked the question:

"So when do I stop?"

⚠️ The honest answer is that this is a chronic treatment, and the trial extension data show most of the weight returns after discontinuation.

Her reaction was not relief:

"So I'm on this forever. Nobody said that."

⚠️ This is the single most important failure in how these medications are being introduced, and it is entirely avoidable.

The information — that stopping produces regain, that this is a treatment for a chronic condition rather than a course — is known, published, and takes thirty seconds to convey.

⚠️ Delivering it at month fourteen, rather than at week zero, converts a reasonable clinical fact into a betrayal.

And her follow-up question was sharper:

"If I stop and it comes back, is that another failure? Because I've got four of those already."

⚠️ That is the psychological cost of nineteen years of weight-cycling meeting a treatment whose discontinuation profile nobody explained — and §24.9 is why it matters clinically and not just emotionally.

What we actually discussed: that nobody frames stopping an antihypertensive as failing at blood pressure · that access and cost may force the decision regardless of clinical preference · ⚠️ and that if she does stop, the maintenance plan and the resistance training are what she keeps.

Analysis

1. ⚠️ "Food noise" reduction is the most consistent reported effect and is rarely mentioned in advance. It is §24.5's mechanism, experienced subjectively.

2. ⚠️ Intake can fall far below intended, and protein falls first — because protein is the macronutrient that requires deliberate effort when appetite is low.

3. Lean mass loss is a management problem, not an inevitability. ⚠️ Protein and resistance training are part of the treatment, not optional adjuncts — and hers were absent for six months.

4. ⚠️ When total intake halves, micronutrient intake halves too (Chapters 13, 14). Nobody had assessed it.

5. The metabolic outcomes were substantial and are the actual point. ⚠️ A1c 7.8 → 6.1, reduced CPAP pressure, less knee pain, lower medication burden.

6. ⚠️ The discontinuation conversation happened fourteen months too late, and turned a known pharmacological fact into a personal betrayal.

7. And her question — "is that another failure?" — is the chapter's thesis arriving in a consultation. ⚠️ Nineteen years of attributing a physiological pattern to personal failing does not switch off because the mechanism has finally been named.

Discussion Questions

1. ⚠️ Write the week-zero conversation. Under 150 words, covering: what to expect, protein and training, side effects, and what happens on stopping. Why isn't this standard?

2. Protein fell to 0.5 g/kg for six months, unnoticed. ⚠️ Whose responsibility? Design the monitoring that would catch it, and say what it costs.

3. ⚠️ "So I'm on this forever." Is that different from a statin or an antihypertensive? Physiologically? Psychologically? Should it be?

4. Her nineteen years of cycling shaped how she received the discontinuation news. ⚠️ How should a clinician account for weight-loss history when introducing a new treatment?

5. ⚠️ Access and cost may force discontinuation regardless of clinical preference (§24's economics). Is it ethical to start someone on a treatment you know they may not be able to continue? Argue both.

6. The outcomes were excellent. ⚠️ Does the management failure in months 3–6 change your assessment of the treatment, or only of the care? Be precise about the difference.

Your Turn

⚠️ This section is for anyone taking, considering, or supporting someone on a GLP-1 receptor agonist — and for clinicians.

Step 1 — The four things to establish before starting:

Step 2 — The protein plan, specifically. ⚠️ With a small appetite, ORDER determines intake.

Target: ____ g/day (1.4–1.6 g/kg of current weight is a reasonable start) ⚠️ Protein source eaten FIRST at each meal: _ What I'll do on a nauseous day: _

Step 3 — ⚠️ Watch for the things that indicate intake has fallen too far:

• [ ] Difficulty rising from a chair, or climbing stairs · [ ] Grip feeling weaker
• [ ] Hair thinning · [ ] Persistent fatigue disproportionate to the weight lost
• [ ] Feeling cold · [ ] ⚠️ Eating under ~1,200 kcal/day for more than a few weeks

⚠️ Any of these: raise it. They are manageable and they are not the price of the treatment.

Step 4 — The micronutrient question (Chapters 13, 14). ⚠️ If total intake has halved, so has everything in it. Ask what should be checked.

Step 5 — And write the maintenance plan now, not later:

⚠️ "If I stop — for any reason, including cost — what do I keep?"

The resistance training. The protein habit. The environment changes. ⚠️ Those are yours and they don't stop when the prescription does — and they are the difference between a regain and a catastrophe.